A GOP-led House committee is directing the Biden administration to account for how it arrived at the decision to reschedule marijuana, while also expressing concerns about cannabis-impaired driving and the market for intoxicating hemp-based cannabinoids.
In a series of reports attached to 2025 Fiscal Year spending bills being considered by the House Appropriations Committee on Wednesday, lawmakers addressed a variety of marijuana-related issues. One of those is the Justice Department’s proposal to move marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA).
Just one day after the committee approved appropriations legislation with a section that would block DOJ from using its funds to reschedule or deschedule cannabis, members are taking up several other bills with reports addressing the proposed scheduling change, as well as other marijuana and psychedelics topics.
In the report for the Agriculture, Rural Development, Food and Drug Administration (Ag/FDA) appropriations bill, there’s an explicit directive for the U.S. Department of Health and Human Services (HHS) inspector general to explain to Congress FDA’s 2023 scientific review into cannabis that led to a Schedule III reclassification recommendation.
That report would need to look at “deviations” from the historical analytical process, justifications for the policy change,
Read full article on Marijuana Moment
